Project Grant R44DE024659

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,493,635 to Sinopia Biosciences Inc. to develop a novel oral compound for treating radiation-induced oral mucositis. The project aims to characterize a selectively-inhibiting compound that demonstrated compelling results in preclinical studies, with the goal of advancing it towards clinical trials. Oral mucositis is a...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $799,270 to Keraceuticals, Inc. to develop novel 1,3-thiourea anticancer compounds for the treatment of oral squamous cell carcinoma (OSCC). The key products and services under this award are: Formulating the lead compound CIDD99 for oral and/or intravenous administration, and rapidly assessing the pharmacokinetics and...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $873,546 to the University of Texas Health Science Center at Houston to develop a biomaterial-enhanced system for targeted localization of engineered probiotic bacteria that secrete the anti-inflammatory cytokine interleukin-10 (IL-10). The goal is to evaluate the use of this "oral micro-drug factory" for host...

This $923,623 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a novel, first-in-class cyclic peptide (VTC-880) for the treatment and prevention of gingivitis and periodontitis. The key objectives are to manufacture the peptide, establish potency and analytical assays, determine optimal formulation and pharmacokinetics in human saliva, assess oral...

This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...

The Department of the Army Medical Command awarded a $711,000 Project Grant to the University of California, San Diego to support research on treating oral cancer pain with LRP1 agonists. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health through innovative medical research solutions for battlefield wounds and health issues that impact Service Members. Specifically, the three-year award beginning September...

This Project Grant award of $513,574.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to elucidate the mechanisms and genetic factors underlying osteonecrosis of the jaw (ONJ), a damaging condition that can occur in patients taking anti-resorptive medications. The key products and services to be delivered through this award include: Elucidating the cellular and molecular mechanisms that give...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $2,805,385 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Oregon Health & Science University (OHSU). The grant's objective is to define T cell-based mechanisms underlying oral mucosal immune-related adverse events (irAEs) caused by anti-PD-1 cancer immunotherapy. The research aims to determine the functional significance of regulatory T cells (Tregs) and Th17 cells in oral...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...